Outcomes of transitioning nivolumab administration from intravenous to subcutaneous: a tertiary UK centre experience (ESMO-IO 2026) - Oct 25, 2026 - Abstract #163P; Pres time: Dec 14, 2026; 05:30 PM - 06:30 PM; Location: Churchill Room; No abstract available
Oncology
|
|
Robert A. Needleman; Keren Broyde; Laura F . Ferro Lopez; Sophia B. Haywood; Praveena Idaikkadar
|